drugset
drugset / Trial / NCT04321070

Bio-equivalence Study With Clinical Endpoints in the Treatment of Acne Vulgaris

NCT04321070 ↗

Phase 1 Completed 550 enrolled Sun Pharmaceutical Industries, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

Bio-equivalence Study With Clinical Endpoints in the Treatment of Acne Vulgaris

Timeline

Start
2019-09-09
Primary completion
2019-12-14
Completion
2020-03-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Clindamycin Unknown — Topical

Indications

acne